Prof Christian Ottensmeier, MD, PhD, FRCP
Christian Ottensmeier is Professor in Experimental Cancer Medicine. He graduated in Münster, Germany and began his specialist training there. After a 3 year training fellowship in the Dana Farber Cancer Institute, he moved to Southampton. He has been a consultant in medical oncology since 2000.
Clinically his interests are thoracic malignancies and melanoma, and he has co-developed a number of national NCRI studies in lung cancer. He managed a broad and active clinical trials portfolio in both lung cancer and melanoma.
Christian leads the Experimental Cancer Medicine Centre in Southampton (http://www.ecmcnetwork.org.uk/) and the early translation of immunotherapeutic strategies into the clinic is his core academic interest. The portfolio of his own trials includes single centre and multicentre studies with both immunotherapeutics developed in house as well as collaborative work with industry. Together with Dr. Katy Rezvani at the Hammersmith Hospital he was successful in obtaining the first cancer trial grant in the UK from the Efficacy and Mechanisms Evaluation board (http://www.eme.ac.uk/) of the National Institute for Health Research in the UK for a vaccine study in haematological malignancies. A parallel strand of investigation examines the effect of chemo-immunotherapy on both anticancer as well as bystander immunity in small cell lung cancer with an anti-CTLA4 antibody.
Christian holds programmatic funding from Leukemia and Lymphoma Research and Cancer Research UK.
Professor of Experimental Medicine
EVEN MORE SEMINARS
Professor Patricia Price Action Radiotherapy
Action Radiotherapy -a charity for radiotherapy patients and professionals.
Glenn Flux Royal Marsden Hospital
The emergence and resurgence of radiotherapeutics for cancer treatment
Prof Adam Waldman MRC Institute of Genetics & Molecular Medicine CANCER RESEARCH UK Imaging
Biomarkers in Adult Glioma
Nirmesh Patel Cambridge Cancer Genomics
Monitoring cancer evolution through smart genomics and liquid biopsies
Emlyn Samuel Cancer Research UK
Brexit: getting the best outcome for research and patients